New gene therapy to help treat premature aging

Researchers at the Caroline Institute of Medicine in Sweden and the Institute of Molecular Oncology in Milan, the Italian Cancer Research Foundation, report in a paper published in the British journal Nature Letters that their studies of patient cells and animal experiments have shown that antisense nucleotide therapy can improve the condition and extend the life span of patients with early-life disordersearly aging is associated with premature aging proteins, which are produced by mutations in the human body that are made of the "nuclear fibrillin A" gene, which affect splintering cellsAntonyonucleotides are synthetic DNA fragments that identify target genes through the base complementary pairing principle and eliminate or reduce lesions by preventing the latter from transcribing and translatingresearchers who studied cell samples in children with premature aging found that telomeres at the ends of these cells were impaired and that some of the telomere-related non-coding RNA was gatheredTelomeres are a kind of structure on the chromosomes of human cells, which is like a "protective cap" on both sides of the shoelaces to prevent wear, which is very important to maintain the stability of chromosomestelomeres shorten as cells divide in normal cells, so telomeres are also thought to be associated with human lifeAfter the researchers targeted to reduce the levels of these RNA by adding antisense oligonucleotide therapy, they found that cell division in the samples tended to be normalin mouse experiments, the researchers increased the maximum life expectancy and life expectancy of mice by 44% and 24%, respectively, after using antisense oligonucleotide therapy in mice with premature aging.